Lucentis effective for proliferative diabetic retinopathy

A clinical trial funded by the National Institutes of Health has found that the drug ranibizumab (Lucentis) is highly effective in treating proliferative diabetic retinopathy. The trial, conducted by the Diabetic Retinopathy Clinical Research Network (DRCR.net) compared Lucentis with a type of laser therapy called panretinal or scatter photocoagulation, which has remained the gold standard for proliferative diabetic retinopathy since the mid-1970s. The findings demonstrate the first major therapy advance in nearly 40 years.

As part of the federal government’s National Institutes of Health (NIH), the National Eye Institute’s mission is to “eliminate vision loss and improve quality of life through vision research.” Learn more about NEI at https://nei.nih.gov

Twitter:   / nateyeinstitute  

LinkedIn:   / national-eye-institute-nei  

Facebook:   / nationaleyeinstitute  

For information on privacy policy and disclaimer, visit: https://www.nei.nih.gov/web-policies/...